STOCK TITAN

Ironwood Pharmaceuticals Inc - IRWD STOCK NEWS

Welcome to our dedicated news page for Ironwood Pharmaceuticals (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ironwood Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ironwood Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
Ironwood Pharmaceuticals Inc

Nasdaq:IRWD

IRWD Rankings

IRWD Stock Data

1.36B
137.03M
2.08%
108.88%
11.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About IRWD

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b